ANVISA approval for CuraTeQ Biologics biosimilars facility in Hyderabad
AUROPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Aurobindo Pharma's wholly owned subsidiary CuraTeQ Biologics received approval from Brazil's health regulator ANVISA for its Hyderabad biosimilars manufacturing facility. The facility cleared a GMP inspection in May 2026 covering four biosimilar products, drug substance and sterile drug product manufacturing, prefilled syringe and vial filling, packaging, and QC labs. The site is already EMA and WHO certified. The approval allows the company to supply biosimilars to Brazil and other Latin American markets.
Positively positions Aurobindo's biosimilars arm CuraTeQ to tap the Brazilian and wider Latin American market, supporting future revenue growth.